You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NamePropofol
Accession NumberDB00818  (APRD01201, EXPT02558, DB05893)
TypeSmall Molecule
GroupsApproved, Investigational, Vet Approved
DescriptionPropofol is an intravenous anaesthetic agent used for induction and maintenance of general anaesthesia. IV administration of propfol is used to induce unconsciousness after which anaesthesia may be maintained using a combination of medications. Recovery from propofol-induced anaesthesia is generally rapid and associated with less frequent side effects (e.g. drowsiness, nausea, vomiting) than with thiopental, methohexital, and etomidate. Propofol may be used prior to diagnostic procedures requiring anaesthesia, in the management of refractory status epilepticus, and for induction and/or maintenance of anaesthesia prior to and during surgeries.
Structure
Thumb
Synonyms
2,6-Bis(1-methylethyl)phenol
2,6-Diisopropylphenol
Diprivan
Disoprivan
Disoprofol
Propofol
Propofol
Propofol
Propofolum
Rapinovet
External Identifiers
  • ICI 35868
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Act PropofolEmulsion10 mgIntravenousActavis Pharma Company2015-11-20Not applicableCanada
DiprivanInjection, emulsion10 mg/mLIntravenousGeneral Injectables & Vaccines, Inc2010-03-01Not applicableUs
DiprivanInjection, emulsion10 mg/mLIntravenousFresenius Kabi USA, LLC2009-11-13Not applicableUs
Diprivan Eml IV 1%Emulsion1 %IntravenousAstrazeneca Canada Inc1993-12-31Not applicableCanada
PMS-propofolEmulsion10 mgIntravenousPharmascience Inc2002-03-01Not applicableCanada
PropofolInjection, emulsion10 mg/mLIntravenousAPP Pharmaceuticals, LLC2009-10-07Not applicableUs
Propofol InjectionEmulsion1 %IntravenousFresenius Kabi Canada Ltd2015-06-01Not applicableCanada
Propofol InjectionEmulsion10 mgIntravenousHospira Healthcare Corporation1998-02-05Not applicableCanada
Propofol InjectionEmulsion10 mgIntravenousNovopharm Limited2000-07-052013-04-01Canada
Propofol InjectionEmulsion10 mgIntravenousHospira Healthcare Corporation2004-04-022011-11-28Canada
Propofol-II InjectionEmulsion10 mgIntravenousHospira Healthcare Corporation2013-06-11Not applicableCanada
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
PropofolInjection, emulsion10 mg/mLIntravenousActavis Pharma, Inc.2015-10-30Not applicableUs
PropofolInjection, emulsion10 mg/mLIntravenousGeneral Injectables and Vaccines, Inc2014-08-21Not applicableUs
PropofolInjection, emulsion10 mg/mLIntravenousTeva Parenteral Medicines, Inc.2007-06-21Not applicableUs
PropofolInjection, emulsion10 mg/mLIntravenousHospira, Inc.2006-03-17Not applicableUs
PropofolInjection, emulsion10 mg/mLIntravenousTeva Parenteral Medicines, Inc.2007-06-21Not applicableUs
PropofolInjection, emulsion10 mg/mLIntravenousSagent Pharmaceuticals2014-07-01Not applicableUs
PropofolInjection, emulsion10 mg/mLIntravenousTeva Parenteral Medicines, Inc.2007-06-21Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
AnepolHa Na Pharm
AnesproBehrens
AnesvanChi Sheng
CritifolAbbott
DisoprivanAstraZeneca
DormofolActavis
FresofolBoryung
GobbifolGobbi
HipnolamAC Farma
HyproCelon
IV-ProClaris Lifesciences
LipuroB. Braun Medical
Oleo-LaxFada
PlofedWarsaw Pharmaceutical Works
ProfolBiogalenic
ProfolenBlausiegel
PropofabbHospira
PropofilAlvia
PropogenGenepharm
PropolipidFresenius
PropovanBharat Serums
PropovenFresenius
ProviveAFT
RecofolBayer
SafolNovell
TrivamHana Pharm
TroypofolTroikaa
UnifolClaris Lifesciences
Brand mixturesNot Available
SaltsNot Available
Categories
UNIIYI7VU623SF
CAS number2078-54-8
WeightAverage: 178.2707
Monoisotopic: 178.135765198
Chemical FormulaC12H18O
InChI KeyOLBCVFGFOZPWHH-UHFFFAOYSA-N
InChI
InChI=1S/C12H18O/c1-8(2)10-6-5-7-11(9(3)4)12(10)13/h5-9,13H,1-4H3
IUPAC Name
2,6-bis(propan-2-yl)phenol
SMILES
CC(C)C1=CC=CC(C(C)C)=C1O
Pharmacology
IndicationUsed for induction and/or maintenance of anaesthesia and for management of refractory status epilepticus.
Structured Indications Not Available
PharmacodynamicsPropofol is a sedative-hypnotic agent for use in the induction and maintenance of anesthesia or sedation. Intravenous injection of a therapeutic dose of propofol produces hypnosis rapidly with minimal excitation, usually within 40 seconds from the start of an injection (the time for one arm-brain circulation).
Mechanism of actionThe action of propofol involves a positive modulation of the inhibitory function of the neurotransmitter gama-aminobutyric acid (GABA) through GABA-A receptors.
TargetKindPharmacological actionActionsOrganismUniProt ID
Gamma-aminobutyric acid receptor subunit beta-2Proteinyes
potentiator
HumanP47870 details
Gamma-aminobutyric acid receptor subunit beta-3Proteinyes
potentiator
HumanP28472 details
Sodium channel protein type 4 subunit alphaProteinunknown
inhibitor
HumanP35499 details
Sodium channel protein type 2 subunit alphaProteinunknown
inhibitor
HumanQ99250 details
GABA-A receptor (anion channel)Protein groupyes
positive allosteric modulator
Humannot applicabledetails
Related Articles
AbsorptionRapid - time to onset of unconsciousness is 15-30 seconds, due to rapid distribution from plasma to the CNS. Distribution is so rapid that peak plasma concentrations cannot be readily measured. Duration of action is 5-10 minutes.
Volume of distribution
  • 60 L/kg [healthy adults]
Protein binding95 to 99%, primarily to serum albumin and hemoglobin
Metabolism

Hepatically metabolized mainly by glucuronidation at the C1-hydroxyl. Hydroxylation of the benzene ring to 4-hydroxypropofol may also occur via CYP2B6 and 2C9 with subsequent conjugation to sulfuric and/or glucuronic acid. Hydroxypropofol has approximately 1/3 of hypnotic activity of propofol.

SubstrateEnzymesProduct
Propofol
4-HydroxypropofolDetails
Propofol
Propofol glucuronideDetails
Propofol glucuronide
Not Available
1-Quinol glucuronideDetails
4-Hydroxypropofol
1-Quinol glucuronideDetails
4-Hydroxypropofol
Not Available
4-Quinol sulfateDetails
Route of eliminationIt is chiefly eliminated by hepatic conjugation to inactive metabolites which are excreted by the kidney.
Half lifeInitial distribution phase t1/2α=1.8-9.5 minutes. Second redistirubtion phase t1/2β=21-70 minutes. Terminal elimination phase t1/2γ=1.5-31 hours.
Clearance
  • 23 – 50 mL/kg/min
  • 1.6 – 3.4 L/min [70 Kg adults]
ToxicityOverdosage may increase pharmacologic and adverse effects or cause death.

IV LD50=53 mg/kg (mice), 42 mg/kg (rats). Oral LD50 (as a solution in soybean oil)=1230 mg/kg (mice), 600 mg/kg (rats)

Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
Interactions
Drug Interactions
DrugInteractionDrug group
1,1,1,2 TetrafluoroethaneThe risk or severity of adverse effects can be increased when Propofol is combined with 1,1,1,2 Tetrafluoroethane.Investigational
7-NitroindazoleThe risk or severity of adverse effects can be increased when Propofol is combined with 7-Nitroindazole.Experimental
AbirateroneThe serum concentration of Propofol can be increased when it is combined with Abiraterone.Approved
AcebutololThe risk or severity of adverse effects can be increased when Acebutolol is combined with Propofol.Approved
AcepromazineThe risk or severity of adverse effects can be increased when Propofol is combined with Acepromazine.Approved, Vet Approved
AceprometazineThe risk or severity of adverse effects can be increased when Propofol is combined with Aceprometazine.Approved
AcetazolamideThe risk or severity of adverse effects can be increased when Propofol is combined with Acetazolamide.Approved, Vet Approved
adipiplonThe risk or severity of adverse effects can be increased when Propofol is combined with adipiplon.Investigational
AgomelatineThe risk or severity of adverse effects can be increased when Propofol is combined with Agomelatine.Approved, Investigational
AldesleukinThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Propofol.Approved
AlfaxaloneThe risk or severity of adverse effects can be increased when Propofol is combined with Alfaxalone.Vet Approved
AlfentanilThe risk or severity of adverse effects can be increased when Alfentanil is combined with Propofol.Approved, Illicit
AliskirenThe risk or severity of adverse effects can be increased when Aliskiren is combined with Propofol.Approved, Investigational
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Propofol is combined with Alphacetylmethadol.Experimental, Illicit
AlprazolamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Propofol.Approved, Illicit, Investigational
AmifostineThe risk or severity of adverse effects can be increased when Amifostine is combined with Propofol.Approved, Investigational
AmilorideThe risk or severity of adverse effects can be increased when Amiloride is combined with Propofol.Approved
AmiodaroneThe metabolism of Propofol can be decreased when combined with Amiodarone.Approved, Investigational
AmisulprideThe risk or severity of adverse effects can be increased when Propofol is combined with Amisulpride.Approved, Investigational
AmitriptylineThe risk or severity of adverse effects can be increased when Propofol is combined with Amitriptyline.Approved
AmlodipineThe risk or severity of adverse effects can be increased when Amlodipine is combined with Propofol.Approved
AmobarbitalThe risk or severity of adverse effects can be increased when Propofol is combined with Amobarbital.Approved, Illicit
AmoxapineThe risk or severity of adverse effects can be increased when Propofol is combined with Amoxapine.Approved
AmperozideThe risk or severity of adverse effects can be increased when Propofol is combined with Amperozide.Experimental
Amphotericin BThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Propofol.Approved, Investigational
Amyl NitriteThe risk or severity of adverse effects can be increased when Amyl Nitrite is combined with Propofol.Approved
AnagrelidePropofol may increase the QTc-prolonging activities of Anagrelide.Approved
ApomorphineThe risk or severity of adverse effects can be increased when Apomorphine is combined with Propofol.Approved, Investigational
ApraclonidineThe risk or severity of adverse effects can be increased when Apraclonidine is combined with Propofol.Approved
AprepitantThe serum concentration of Propofol can be increased when it is combined with Aprepitant.Approved, Investigational
AripiprazoleAripiprazole may increase the hypotensive activities of Propofol.Approved, Investigational
ArmodafinilThe metabolism of Propofol can be decreased when combined with Armodafinil.Approved, Investigational
ArotinololThe risk or severity of adverse effects can be increased when Arotinolol is combined with Propofol.Approved
Arsenic trioxidePropofol may increase the QTc-prolonging activities of Arsenic trioxide.Approved, Investigational
ArtemetherPropofol may increase the QTc-prolonging activities of Artemether.Approved
ArticaineThe risk or severity of adverse effects can be increased when Propofol is combined with Articaine.Approved
AsenapinePropofol may increase the QTc-prolonging activities of Asenapine.Approved
AtazanavirThe metabolism of Propofol can be decreased when combined with Atazanavir.Approved, Investigational
AtenololThe risk or severity of adverse effects can be increased when Atenolol is combined with Propofol.Approved
AtomoxetineThe metabolism of Propofol can be decreased when combined with Atomoxetine.Approved
AzaperoneThe risk or severity of adverse effects can be increased when Propofol is combined with Azaperone.Vet Approved
AzelastinePropofol may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
AzelastineThe risk or severity of adverse effects can be increased when Propofol is combined with Azelastine.Approved
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Propofol.Approved
AzithromycinPropofol may increase the QTc-prolonging activities of Azithromycin.Approved
BaclofenThe risk or severity of adverse effects can be increased when Propofol is combined with Baclofen.Approved
BarbexacloneBarbexaclone may increase the hypotensive activities of Propofol.Experimental
BarbitalThe risk or severity of adverse effects can be increased when Propofol is combined with Barbital.Illicit
BarnidipineThe risk or severity of adverse effects can be increased when Barnidipine is combined with Propofol.Approved
BedaquilinePropofol may increase the QTc-prolonging activities of Bedaquiline.Approved
BenazeprilThe risk or severity of adverse effects can be increased when Benazepril is combined with Propofol.Approved, Investigational
BendroflumethiazideThe risk or severity of adverse effects can be increased when Bendroflumethiazide is combined with Propofol.Approved
BenperidolThe risk or severity of adverse effects can be increased when Propofol is combined with Benperidol.Investigational
BenzocaineThe risk or severity of adverse effects can be increased when Propofol is combined with Benzocaine.Approved
Benzyl alcoholThe risk or severity of adverse effects can be increased when Propofol is combined with Benzyl alcohol.Approved
BepridilThe risk or severity of adverse effects can be increased when Bepridil is combined with Propofol.Approved, Withdrawn
BetaxololThe metabolism of Propofol can be decreased when combined with Betaxolol.Approved
BexaroteneThe serum concentration of Propofol can be decreased when it is combined with Bexarotene.Approved, Investigational
BisoprololThe risk or severity of adverse effects can be increased when Bisoprolol is combined with Propofol.Approved
BoceprevirThe metabolism of Propofol can be decreased when combined with Boceprevir.Approved
BortezomibThe metabolism of Propofol can be decreased when combined with Bortezomib.Approved, Investigational
BosentanThe serum concentration of Propofol can be decreased when it is combined with Bosentan.Approved, Investigational
BretyliumThe risk or severity of adverse effects can be increased when Bretylium is combined with Propofol.Approved
BrexpiprazoleThe risk or severity of adverse effects can be increased when Propofol is combined with Brexpiprazole.Approved
BrimonidineThe risk or severity of adverse effects can be increased when Propofol is combined with Brimonidine.Approved
BrimonidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Propofol.Approved
BromazepamThe risk or severity of adverse effects can be increased when Propofol is combined with Bromazepam.Approved, Illicit
BromocriptineThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Propofol.Approved, Investigational
BrompheniramineThe risk or severity of adverse effects can be increased when Propofol is combined with Brompheniramine.Approved
BrotizolamThe risk or severity of adverse effects can be increased when Propofol is combined with Brotizolam.Approved, Withdrawn
BumetanideThe risk or severity of adverse effects can be increased when Bumetanide is combined with Propofol.Approved
BupivacaineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Propofol.Approved, Investigational
BuprenorphinePropofol may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved, Illicit, Investigational, Vet Approved
BupropionThe metabolism of Propofol can be decreased when combined with Bupropion.Approved
BuspironeThe risk or severity of adverse effects can be increased when Buspirone is combined with Propofol.Approved, Investigational
ButabarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Propofol.Approved, Illicit
ButacaineThe risk or severity of adverse effects can be increased when Propofol is combined with Butacaine.Vet Approved
ButalbitalThe risk or severity of adverse effects can be increased when Propofol is combined with Butalbital.Approved, Illicit
ButambenThe risk or severity of adverse effects can be increased when Propofol is combined with Butamben.Approved
ButethalThe risk or severity of adverse effects can be increased when Propofol is combined with Butethal.Approved, Illicit
ButorphanolThe risk or severity of adverse effects can be increased when Butorphanol is combined with Propofol.Approved, Illicit, Vet Approved
CaffeineThe metabolism of Propofol can be decreased when combined with Caffeine.Approved
CanagliflozinThe risk or severity of adverse effects can be increased when Canagliflozin is combined with Propofol.Approved
CandesartanThe risk or severity of adverse effects can be increased when Candesartan is combined with Propofol.Approved
CapecitabineThe metabolism of Propofol can be decreased when combined with Capecitabine.Approved, Investigational
CaptoprilThe risk or severity of adverse effects can be increased when Captopril is combined with Propofol.Approved
CarbamazepineThe metabolism of Propofol can be increased when combined with Carbamazepine.Approved, Investigational
CarbetocinThe risk or severity of adverse effects can be increased when Carbetocin is combined with Propofol.Approved
CarbinoxamineThe risk or severity of adverse effects can be increased when Propofol is combined with Carbinoxamine.Approved
CarfentanilThe risk or severity of adverse effects can be increased when Propofol is combined with Carfentanil.Illicit, Vet Approved
CarisoprodolThe risk or severity of adverse effects can be increased when Propofol is combined with Carisoprodol.Approved
CarteololThe risk or severity of adverse effects can be increased when Carteolol is combined with Propofol.Approved
CarvedilolThe risk or severity of adverse effects can be increased when Carvedilol is combined with Propofol.Approved, Investigational
CelecoxibThe metabolism of Propofol can be decreased when combined with Celecoxib.Approved, Investigational
CeritinibThe serum concentration of Propofol can be increased when it is combined with Ceritinib.Approved
CetirizineThe risk or severity of adverse effects can be increased when Propofol is combined with Cetirizine.Approved
Chloral hydrateThe risk or severity of adverse effects can be increased when Propofol is combined with Chloral hydrate.Approved, Illicit, Vet Approved
ChloramphenicolThe metabolism of Propofol can be decreased when combined with Chloramphenicol.Approved, Vet Approved
ChlordiazepoxideThe risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Propofol.Approved, Illicit
ChlormezanoneThe risk or severity of adverse effects can be increased when Propofol is combined with Chlormezanone.Approved, Withdrawn
ChloroprocaineThe risk or severity of adverse effects can be increased when Propofol is combined with Chloroprocaine.Approved
ChloroquinePropofol may increase the QTc-prolonging activities of Chloroquine.Approved, Vet Approved
ChlorothiazideThe risk or severity of adverse effects can be increased when Chlorothiazide is combined with Propofol.Approved, Vet Approved
ChlorphenamineThe risk or severity of adverse effects can be increased when Propofol is combined with Chlorphenamine.Approved
ChlorpromazinePropofol may increase the QTc-prolonging activities of Chlorpromazine.Approved, Vet Approved
ChlorprothixeneThe risk or severity of adverse effects can be increased when Propofol is combined with Chlorprothixene.Approved, Withdrawn
ChlorthalidoneThe risk or severity of adverse effects can be increased when Chlorthalidone is combined with Propofol.Approved
ChlorzoxazoneThe risk or severity of adverse effects can be increased when Propofol is combined with Chlorzoxazone.Approved
CholecalciferolThe metabolism of Propofol can be decreased when combined with Cholecalciferol.Approved, Nutraceutical
CilazaprilThe risk or severity of adverse effects can be increased when Cilazapril is combined with Propofol.Approved
CilnidipineThe risk or severity of adverse effects can be increased when Cilnidipine is combined with Propofol.Approved
CimetidineThe metabolism of Propofol can be decreased when combined with Cimetidine.Approved
CinacalcetThe metabolism of Propofol can be decreased when combined with Cinacalcet.Approved
CinchocaineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Propofol.Approved, Vet Approved
CiprofloxacinPropofol may increase the QTc-prolonging activities of Ciprofloxacin.Approved, Investigational
CisapridePropofol may increase the QTc-prolonging activities of Cisapride.Approved, Investigational, Withdrawn
CitalopramPropofol may increase the QTc-prolonging activities of Citalopram.Approved
ClarithromycinThe metabolism of Propofol can be decreased when combined with Clarithromycin.Approved
ClemastineThe metabolism of Propofol can be decreased when combined with Clemastine.Approved
ClevidipineThe risk or severity of adverse effects can be increased when Clevidipine is combined with Propofol.Approved
ClidiniumThe risk or severity of adverse effects can be increased when Propofol is combined with Clidinium.Approved
ClobazamThe metabolism of Propofol can be decreased when combined with Clobazam.Approved, Illicit
ClofarabineThe risk or severity of adverse effects can be increased when Clofarabine is combined with Propofol.Approved, Investigational
clomethiazoleThe risk or severity of adverse effects can be increased when Propofol is combined with clomethiazole.Investigational
ClomipramineThe metabolism of Propofol can be decreased when combined with Clomipramine.Approved, Vet Approved
ClonazepamThe risk or severity of adverse effects can be increased when Propofol is combined with Clonazepam.Approved, Illicit
ClonidineThe risk or severity of adverse effects can be increased when Propofol is combined with Clonidine.Approved
ClopidogrelThe metabolism of Propofol can be decreased when combined with Clopidogrel.Approved, Nutraceutical
ClorazepateThe risk or severity of adverse effects can be increased when Clorazepate is combined with Propofol.Approved, Illicit
ClotrimazoleThe metabolism of Propofol can be decreased when combined with Clotrimazole.Approved, Vet Approved
ClozapinePropofol may increase the QTc-prolonging activities of Clozapine.Approved
CobicistatThe serum concentration of Propofol can be increased when it is combined with Cobicistat.Approved
CocaineThe metabolism of Propofol can be decreased when combined with Cocaine.Approved, Illicit
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Propofol.Approved, Illicit
ConivaptanThe serum concentration of Propofol can be increased when it is combined with Conivaptan.Approved, Investigational
CrizotinibPropofol may increase the QTc-prolonging activities of Crizotinib.Approved
CyclizineThe risk or severity of adverse effects can be increased when Propofol is combined with Cyclizine.Approved
CyclobenzaprineThe risk or severity of adverse effects can be increased when Propofol is combined with Cyclobenzaprine.Approved
CyclosporineThe metabolism of Propofol can be decreased when combined with Cyclosporine.Approved, Investigational, Vet Approved
CyproheptadineThe risk or severity of adverse effects can be increased when Propofol is combined with Cyproheptadine.Approved
Cyproterone acetateThe serum concentration of Propofol can be decreased when it is combined with Cyproterone acetate.Approved, Investigational
DabrafenibThe serum concentration of Propofol can be decreased when it is combined with Dabrafenib.Approved
DantroleneThe risk or severity of adverse effects can be increased when Propofol is combined with Dantrolene.Approved
DapagliflozinThe risk or severity of adverse effects can be increased when Dapagliflozin is combined with Propofol.Approved
DapiprazoleThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Propofol.Approved
DapoxetineThe risk or severity of adverse effects can be increased when Propofol is combined with Dapoxetine.Investigational
DarifenacinThe metabolism of Propofol can be decreased when combined with Darifenacin.Approved, Investigational
DarunavirThe serum concentration of Propofol can be increased when it is combined with Darunavir.Approved
DasatinibThe serum concentration of Propofol can be increased when it is combined with Dasatinib.Approved, Investigational
DeferasiroxThe serum concentration of Propofol can be decreased when it is combined with Deferasirox.Approved, Investigational
DelavirdineThe metabolism of Propofol can be decreased when combined with Delavirdine.Approved
deramciclaneThe risk or severity of adverse effects can be increased when Propofol is combined with deramciclane.Investigational
DesfluraneThe risk or severity of adverse effects can be increased when Propofol is combined with Desflurane.Approved
DesipramineThe metabolism of Propofol can be decreased when combined with Desipramine.Approved
DesloratadineThe risk or severity of adverse effects can be increased when Propofol is combined with Desloratadine.Approved, Investigational
DesvenlafaxineThe risk or severity of adverse effects can be increased when Propofol is combined with Desvenlafaxine.Approved
DetomidineThe risk or severity of adverse effects can be increased when Propofol is combined with Detomidine.Vet Approved
DexamethasoneThe serum concentration of Propofol can be decreased when it is combined with Dexamethasone.Approved, Investigational, Vet Approved
DexbrompheniramineThe risk or severity of adverse effects can be increased when Propofol is combined with Dexbrompheniramine.Approved
DexmedetomidineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Propofol.Approved, Vet Approved
DextromoramideThe risk or severity of adverse effects can be increased when Propofol is combined with Dextromoramide.Experimental, Illicit
DextropropoxypheneThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Propofol.Approved, Illicit, Withdrawn
DezocineThe risk or severity of adverse effects can be increased when Propofol is combined with Dezocine.Approved
DiazepamThe risk or severity of adverse effects can be increased when Propofol is combined with Diazepam.Approved, Illicit, Vet Approved
DiclofenamideThe risk or severity of adverse effects can be increased when Diclofenamide is combined with Propofol.Approved
DifenoxinThe risk or severity of adverse effects can be increased when Propofol is combined with Difenoxin.Approved, Illicit
DihydrocodeineThe risk or severity of adverse effects can be increased when Propofol is combined with Dihydrocodeine.Approved, Illicit
DihydroergotamineThe metabolism of Propofol can be decreased when combined with Dihydroergotamine.Approved
DihydroetorphineThe risk or severity of adverse effects can be increased when Propofol is combined with Dihydroetorphine.Experimental, Illicit
DihydromorphineThe risk or severity of adverse effects can be increased when Propofol is combined with Dihydromorphine.Experimental, Illicit
DiltiazemThe metabolism of Propofol can be decreased when combined with Diltiazem.Approved
DimenhydrinateThe risk or severity of adverse effects can be increased when Propofol is combined with Dimenhydrinate.Approved
DinutuximabThe risk or severity of adverse effects can be increased when Dinutuximab is combined with Propofol.Approved
DiphenhydramineThe metabolism of Propofol can be decreased when combined with Diphenhydramine.Approved
DiphenoxylateThe risk or severity of adverse effects can be increased when Propofol is combined with Diphenoxylate.Approved, Illicit
DipyridamoleThe risk or severity of adverse effects can be increased when Dipyridamole is combined with Propofol.Approved
DisopyramidePropofol may increase the QTc-prolonging activities of Disopyramide.Approved
DisulfiramThe metabolism of Propofol can be decreased when combined with Disulfiram.Approved
DofetilideThe serum concentration of Dofetilide can be increased when it is combined with Propofol.Approved
DolasetronPropofol may increase the QTc-prolonging activities of Dolasetron.Approved
DomperidonePropofol may increase the QTc-prolonging activities of Domperidone.Approved, Investigational, Vet Approved
DoramectinThe risk or severity of adverse effects can be increased when Propofol is combined with Doramectin.Vet Approved
DoxazosinThe risk or severity of adverse effects can be increased when Doxazosin is combined with Propofol.Approved
DoxepinThe risk or severity of adverse effects can be increased when Propofol is combined with Doxepin.Approved
DoxorubicinThe metabolism of Propofol can be decreased when combined with Doxorubicin.Approved, Investigational
DoxycyclineThe metabolism of Propofol can be decreased when combined with Doxycycline.Approved, Investigational, Vet Approved
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Propofol.Approved, Vet Approved
DPDPEThe risk or severity of adverse effects can be increased when Propofol is combined with DPDPE.Investigational
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Propofol.Approved, Illicit
DronedaronePropofol may increase the QTc-prolonging activities of Dronedarone.Approved
DroperidolDroperidol may increase the central nervous system depressant (CNS depressant) activities of Propofol.Approved, Vet Approved
DrotebanolThe risk or severity of adverse effects can be increased when Propofol is combined with Drotebanol.Experimental, Illicit
DuloxetinePropofol may increase the orthostatic hypotensive activities of Duloxetine.Approved
DyclonineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Propofol.Approved
EcgonineThe risk or severity of adverse effects can be increased when Propofol is combined with Ecgonine.Experimental, Illicit
ECGONINE METHYL ESTERThe risk or severity of adverse effects can be increased when Propofol is combined with ECGONINE METHYL ESTER.Experimental
EcopipamThe risk or severity of adverse effects can be increased when Propofol is combined with Ecopipam.Investigational
EfavirenzThe serum concentration of Propofol can be decreased when it is combined with Efavirenz.Approved, Investigational
EfonidipineThe risk or severity of adverse effects can be increased when Efonidipine is combined with Propofol.Approved
EliglustatPropofol may increase the QTc-prolonging activities of Eliglustat.Approved
EmpagliflozinThe risk or severity of adverse effects can be increased when Empagliflozin is combined with Propofol.Approved
EnalaprilThe risk or severity of adverse effects can be increased when Enalapril is combined with Propofol.Approved, Vet Approved
EnalaprilatThe risk or severity of adverse effects can be increased when Enalaprilat is combined with Propofol.Approved
EnfluraneThe risk or severity of adverse effects can be increased when Enflurane is combined with Propofol.Approved, Vet Approved
EntacaponeThe risk or severity of adverse effects can be increased when Propofol is combined with Entacapone.Approved, Investigational
EnzalutamideThe serum concentration of Propofol can be decreased when it is combined with Enzalutamide.Approved
EplerenoneThe risk or severity of adverse effects can be increased when Eplerenone is combined with Propofol.Approved
EpoprostenolThe risk or severity of adverse effects can be increased when Epoprostenol is combined with Propofol.Approved
EprosartanThe risk or severity of adverse effects can be increased when Eprosartan is combined with Propofol.Approved
ErythromycinPropofol may increase the QTc-prolonging activities of Erythromycin.Approved, Vet Approved
EscitalopramPropofol may increase the QTc-prolonging activities of Escitalopram.Approved, Investigational
Eslicarbazepine acetateThe serum concentration of Propofol can be decreased when it is combined with Eslicarbazepine acetate.Approved
EsmololThe risk or severity of adverse effects can be increased when Esmolol is combined with Propofol.Approved
EsomeprazoleThe metabolism of Propofol can be decreased when combined with Esomeprazole.Approved, Investigational
EstazolamThe risk or severity of adverse effects can be increased when Propofol is combined with Estazolam.Approved, Illicit
EszopicloneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Propofol.Approved
Etacrynic acidThe risk or severity of adverse effects can be increased when Etacrynic acid is combined with Propofol.Approved
EthanolPropofol may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved
EthchlorvynolThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Propofol.Approved, Illicit, Withdrawn
EthosuximideThe risk or severity of adverse effects can be increased when Propofol is combined with Ethosuximide.Approved
EthotoinThe risk or severity of adverse effects can be increased when Propofol is combined with Ethotoin.Approved
Ethyl carbamateThe risk or severity of adverse effects can be increased when Propofol is combined with Ethyl carbamate.Withdrawn
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Propofol is combined with Ethyl loflazepate.Approved, Illicit
EthylmorphineThe risk or severity of adverse effects can be increased when Propofol is combined with Ethylmorphine.Approved, Illicit
EtidocaineThe risk or severity of adverse effects can be increased when Propofol is combined with Etidocaine.Approved
EtifoxineThe risk or severity of adverse effects can be increased when Propofol is combined with Etifoxine.Withdrawn
EtizolamThe risk or severity of adverse effects can be increased when Propofol is combined with Etizolam.Approved
EtomidateThe risk or severity of adverse effects can be increased when Etomidate is combined with Propofol.Approved
EtoperidoneThe risk or severity of adverse effects can be increased when Propofol is combined with Etoperidone.Approved
EtorphineThe risk or severity of adverse effects can be increased when Propofol is combined with Etorphine.Illicit, Vet Approved
EtravirineThe serum concentration of Propofol can be decreased when it is combined with Etravirine.Approved
EzogabineThe risk or severity of adverse effects can be increased when Propofol is combined with Ezogabine.Approved
FelbamateThe risk or severity of adverse effects can be increased when Propofol is combined with Felbamate.Approved
FelodipineThe metabolism of Propofol can be decreased when combined with Felodipine.Approved, Investigational
FencamfamineThe risk or severity of adverse effects can be increased when Propofol is combined with Fencamfamine.Approved, Illicit, Withdrawn
FenoldopamThe risk or severity of adverse effects can be increased when Fenoldopam is combined with Propofol.Approved
FentanylThe risk or severity of adverse effects can be increased when Fentanyl is combined with Propofol.Approved, Illicit, Investigational, Vet Approved
FesoterodineThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Propofol.Approved
FexofenadineThe risk or severity of adverse effects can be increased when Propofol is combined with Fexofenadine.Approved
FimasartanThe risk or severity of adverse effects can be increased when Fimasartan is combined with Propofol.Approved
FlecainidePropofol may increase the QTc-prolonging activities of Flecainide.Approved, Withdrawn
FlibanserinThe serum concentration of Flibanserin can be increased when it is combined with Propofol.Approved
FloxuridineThe metabolism of Propofol can be decreased when combined with Floxuridine.Approved
FluconazoleThe metabolism of Propofol can be decreased when combined with Fluconazole.Approved
FludiazepamThe risk or severity of adverse effects can be increased when Propofol is combined with Fludiazepam.Approved, Illicit
FlunarizineThe risk or severity of adverse effects can be increased when Propofol is combined with Flunarizine.Approved
FlunitrazepamThe risk or severity of adverse effects can be increased when Propofol is combined with Flunitrazepam.Approved, Illicit
FluorouracilThe metabolism of Propofol can be decreased when combined with Fluorouracil.Approved
FluoxetinePropofol may increase the QTc-prolonging activities of Fluoxetine.Approved, Vet Approved
FlupentixolPropofol may increase the QTc-prolonging activities of Flupentixol.Approved, Withdrawn
FluphenazineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Propofol.Approved
FlurazepamThe risk or severity of adverse effects can be increased when Flurazepam is combined with Propofol.Approved, Illicit
FluspirileneThe risk or severity of adverse effects can be increased when Propofol is combined with Fluspirilene.Approved
Fluticasone PropionateThe risk or severity of adverse effects can be increased when Propofol is combined with Fluticasone Propionate.Approved
FluvastatinThe metabolism of Propofol can be decreased when combined with Fluvastatin.Approved
FluvoxamineThe metabolism of Propofol can be decreased when combined with Fluvoxamine.Approved, Investigational
FosamprenavirThe metabolism of Propofol can be decreased when combined with Fosamprenavir.Approved
FosaprepitantThe serum concentration of Propofol can be increased when it is combined with Fosaprepitant.Approved
FosinoprilThe risk or severity of adverse effects can be increased when Fosinopril is combined with Propofol.Approved
FosphenytoinThe metabolism of Propofol can be increased when combined with Fosphenytoin.Approved
FospropofolThe risk or severity of adverse effects can be increased when Propofol is combined with Fospropofol.Approved, Illicit
FurosemideThe risk or severity of adverse effects can be increased when Furosemide is combined with Propofol.Approved, Vet Approved
Fusidic AcidThe serum concentration of Propofol can be increased when it is combined with Fusidic Acid.Approved
GabapentinThe risk or severity of adverse effects can be increased when Propofol is combined with Gabapentin.Approved, Investigational
gabapentin enacarbilThe risk or severity of adverse effects can be increased when Propofol is combined with gabapentin enacarbil.Approved
Gadobenic acidPropofol may increase the QTc-prolonging activities of Gadobenic acid.Approved
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Propofol is combined with Gamma Hydroxybutyric Acid.Approved, Illicit
GemfibrozilThe metabolism of Propofol can be decreased when combined with Gemfibrozil.Approved
GemifloxacinPropofol may increase the QTc-prolonging activities of Gemifloxacin.Approved, Investigational
GepironeThe risk or severity of adverse effects can be increased when Propofol is combined with Gepirone.Investigational
GlutethimideThe risk or severity of adverse effects can be increased when Propofol is combined with Glutethimide.Approved, Illicit
GoserelinPropofol may increase the QTc-prolonging activities of Goserelin.Approved
GranisetronPropofol may increase the QTc-prolonging activities of Granisetron.Approved, Investigational
GuanfacineThe risk or severity of adverse effects can be increased when Propofol is combined with Guanfacine.Approved, Investigational
HalazepamThe risk or severity of adverse effects can be increased when Halazepam is combined with Propofol.Approved, Illicit, Withdrawn
HaloperidolPropofol may increase the QTc-prolonging activities of Haloperidol.Approved
HalothaneThe risk or severity of adverse effects can be increased when Propofol is combined with Halothane.Approved, Vet Approved
HeroinThe risk or severity of adverse effects can be increased when Propofol is combined with Heroin.Approved, Illicit
HexobarbitalThe risk or severity of adverse effects can be increased when Propofol is combined with Hexobarbital.Approved
HydralazineThe risk or severity of adverse effects can be increased when Hydralazine is combined with Propofol.Approved
HydrochlorothiazideThe risk or severity of adverse effects can be increased when Hydrochlorothiazide is combined with Propofol.Approved, Vet Approved
HydrocodonePropofol may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Illicit
HydroflumethiazideThe risk or severity of adverse effects can be increased when Hydroflumethiazide is combined with Propofol.Approved
HydromorphoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Propofol.Approved, Illicit
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Propofol.Approved
IbutilidePropofol may increase the QTc-prolonging activities of Ibutilide.Approved
IdelalisibThe serum concentration of Propofol can be increased when it is combined with Idelalisib.Approved
IloperidonePropofol may increase the QTc-prolonging activities of Iloperidone.Approved
IloprostThe risk or severity of adverse effects can be increased when Iloprost is combined with Propofol.Approved, Investigational
ImatinibThe metabolism of Propofol can be decreased when combined with Imatinib.Approved
ImidaprilThe risk or severity of adverse effects can be increased when Imidapril is combined with Propofol.Investigational
ImipramineThe metabolism of Propofol can be decreased when combined with Imipramine.Approved
IndalpineThe risk or severity of adverse effects can be increased when Propofol is combined with Indalpine.Investigational, Withdrawn
IndapamideThe risk or severity of adverse effects can be increased when Indapamide is combined with Propofol.Approved
IndinavirThe metabolism of Propofol can be decreased when combined with Indinavir.Approved
IndoraminThe risk or severity of adverse effects can be increased when Indoramin is combined with Propofol.Withdrawn
IrbesartanThe metabolism of Propofol can be decreased when combined with Irbesartan.Approved, Investigational
IrinotecanThe serum concentration of the active metabolites of Irinotecan can be increased when Irinotecan is used in combination with Propofol.Approved, Investigational
IsavuconazoniumThe metabolism of Propofol can be decreased when combined with Isavuconazonium.Approved, Investigational
IsocarboxazidThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Propofol.Approved
IsofluraneThe risk or severity of adverse effects can be increased when Isoflurane is combined with Propofol.Approved, Vet Approved
IsoniazidThe metabolism of Propofol can be decreased when combined with Isoniazid.Approved
Isosorbide DinitrateThe risk or severity of adverse effects can be increased when Isosorbide Dinitrate is combined with Propofol.Approved
Isosorbide MononitrateThe risk or severity of adverse effects can be increased when Isosorbide Mononitrate is combined with Propofol.Approved
IsoxsuprineThe risk or severity of adverse effects can be increased when Isoxsuprine is combined with Propofol.Approved, Withdrawn
IsradipineThe metabolism of Propofol can be decreased when combined with Isradipine.Approved
ItraconazoleThe metabolism of Propofol can be decreased when combined with Itraconazole.Approved, Investigational
IvacaftorThe serum concentration of Propofol can be increased when it is combined with Ivacaftor.Approved
KetamineThe risk or severity of adverse effects can be increased when Propofol is combined with Ketamine.Approved, Vet Approved
KetazolamThe risk or severity of adverse effects can be increased when Propofol is combined with Ketazolam.Approved
KetobemidoneThe risk or severity of adverse effects can be increased when Propofol is combined with Ketobemidone.Approved
KetoconazoleThe metabolism of Propofol can be decreased when combined with Ketoconazole.Approved, Investigational
LabetalolThe risk or severity of adverse effects can be increased when Labetalol is combined with Propofol.Approved
LacidipineThe risk or severity of adverse effects can be increased when Lacidipine is combined with Propofol.Approved
LamotrigineThe risk or severity of adverse effects can be increased when Propofol is combined with Lamotrigine.Approved, Investigational
LapatinibThe metabolism of Propofol can be decreased when combined with Lapatinib.Approved, Investigational
LeflunomideThe metabolism of Propofol can be decreased when combined with Leflunomide.Approved, Investigational
LenvatinibPropofol may increase the QTc-prolonging activities of Lenvatinib.Approved
LercanidipineThe risk or severity of adverse effects can be increased when Lercanidipine is combined with Propofol.Approved, Investigational
LeuprolidePropofol may increase the QTc-prolonging activities of Leuprolide.Approved, Investigational
LevetiracetamThe risk or severity of adverse effects can be increased when Propofol is combined with Levetiracetam.Approved, Investigational
LevobunololThe risk or severity of adverse effects can be increased when Levobunolol is combined with Propofol.Approved
LevobupivacaineThe risk or severity of adverse effects can be increased when Propofol is combined with Levobupivacaine.Approved
LevocabastineThe risk or severity of adverse effects can be increased when Propofol is combined with Levocabastine.Approved
LevocetirizineThe risk or severity of adverse effects can be increased when Propofol is combined with Levocetirizine.Approved
LevodopaPropofol may increase the orthostatic hypotensive activities of Levodopa.Approved
LevofloxacinPropofol may increase the QTc-prolonging activities of Levofloxacin.Approved, Investigational
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Propofol is combined with Levomethadyl Acetate.Approved
LevomilnacipranThe risk or severity of adverse effects can be increased when Propofol is combined with Levomilnacipran.Approved
LevorphanolThe risk or severity of adverse effects can be increased when Propofol is combined with Levorphanol.Approved
LevosimendanThe risk or severity of adverse effects can be increased when Levosimendan is combined with Propofol.Approved, Investigational
LidocaineThe metabolism of Propofol can be decreased when combined with Lidocaine.Approved, Vet Approved
LisinoprilThe risk or severity of adverse effects can be increased when Lisinopril is combined with Propofol.Approved, Investigational
LithiumThe risk or severity of adverse effects can be increased when Propofol is combined with Lithium.Approved
LofentanilThe risk or severity of adverse effects can be increased when Propofol is combined with Lofentanil.Illicit
LofexidineThe risk or severity of adverse effects can be increased when Lofexidine is combined with Propofol.Approved, Investigational
LomitapideThe serum concentration of Lomitapide can be increased when it is combined with Propofol.Approved
LopinavirThe metabolism of Propofol can be decreased when combined with Lopinavir.Approved
LoratadineThe risk or severity of adverse effects can be increased when Propofol is combined with Loratadine.Approved
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Propofol.Approved
LorcaserinThe metabolism of Propofol can be decreased when combined with Lorcaserin.Approved
LosartanThe metabolism of Propofol can be decreased when combined with Losartan.Approved
LovastatinThe metabolism of Propofol can be decreased when combined with Lovastatin.Approved, Investigational
LoxapineThe risk or severity of adverse effects can be increased when Loxapine is combined with Propofol.Approved
Lu AA21004The risk or severity of adverse effects can be increased when Propofol is combined with Lu AA21004.Investigational
LuliconazoleThe serum concentration of Propofol can be increased when it is combined with Luliconazole.Approved
LumacaftorThe serum concentration of Propofol can be increased when it is combined with Lumacaftor.Approved
LumefantrinePropofol may increase the QTc-prolonging activities of Lumefantrine.Approved
LurasidoneThe risk or severity of adverse effects can be increased when Propofol is combined with Lurasidone.Approved
Magnesium SulfateMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Propofol.Approved, Vet Approved
MannitolThe risk or severity of adverse effects can be increased when Mannitol is combined with Propofol.Approved, Investigational
MaprotilineThe risk or severity of adverse effects can be increased when Propofol is combined with Maprotiline.Approved
MecamylamineThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Propofol.Approved
MeclizineThe risk or severity of adverse effects can be increased when Propofol is combined with Meclizine.Approved
MedetomidineThe risk or severity of adverse effects can be increased when Propofol is combined with Medetomidine.Vet Approved
MelatoninThe risk or severity of adverse effects can be increased when Propofol is combined with Melatonin.Approved, Nutraceutical, Vet Approved
MelperoneThe risk or severity of adverse effects can be increased when Propofol is combined with Melperone.Approved
MepivacaineThe risk or severity of adverse effects can be increased when Propofol is combined with Mepivacaine.Approved, Vet Approved
MeprobamateThe risk or severity of adverse effects can be increased when Meprobamate is combined with Propofol.Approved, Illicit
MesoridazineThe risk or severity of adverse effects can be increased when Propofol is combined with Mesoridazine.Approved
MetaxaloneThe risk or severity of adverse effects can be increased when Propofol is combined with Metaxalone.Approved
MethadonePropofol may increase the QTc-prolonging activities of Methadone.Approved
Methadyl AcetateThe risk or severity of adverse effects can be increased when Propofol is combined with Methadyl Acetate.Approved, Illicit
MethapyrileneThe risk or severity of adverse effects can be increased when Propofol is combined with Methapyrilene.Withdrawn
MethaqualoneThe risk or severity of adverse effects can be increased when Propofol is combined with Methaqualone.Illicit, Withdrawn
MethazolamideThe risk or severity of adverse effects can be increased when Methazolamide is combined with Propofol.Approved
MethocarbamolThe risk or severity of adverse effects can be increased when Propofol is combined with Methocarbamol.Approved, Vet Approved
MethohexitalThe risk or severity of adverse effects can be increased when Methohexital is combined with Propofol.Approved
MethotrimeprazinePropofol may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved
MethoxyfluraneThe risk or severity of adverse effects can be increased when Propofol is combined with Methoxyflurane.Approved, Vet Approved
MethsuximideThe risk or severity of adverse effects can be increased when Propofol is combined with Methsuximide.Approved
MethyclothiazideThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Propofol.Approved
MethyldopaThe risk or severity of adverse effects can be increased when Methyldopa is combined with Propofol.Approved
MethylphenobarbitalThe risk or severity of adverse effects can be increased when Propofol is combined with Methylphenobarbital.Approved
MetipranololThe risk or severity of adverse effects can be increased when Metipranolol is combined with Propofol.Approved
MetolazoneThe risk or severity of adverse effects can be increased when Metolazone is combined with Propofol.Approved
MetoprololThe serum concentration of Metoprolol can be increased when it is combined with Propofol.Approved, Investigational
MetyrosinePropofol may increase the sedative activities of Metyrosine.Approved
MexiletineThe metabolism of Propofol can be decreased when combined with Mexiletine.Approved
MidazolamThe serum concentration of Propofol can be increased when it is combined with Midazolam.Approved, Illicit
MifepristoneThe serum concentration of Propofol can be increased when it is combined with Mifepristone.Approved, Investigational
MilnacipranThe risk or severity of adverse effects can be increased when Propofol is combined with Milnacipran.Approved
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Propofol.Approved, Investigational
MinoxidilThe risk or severity of adverse effects can be increased when Minoxidil is combined with Propofol.Approved
MirabegronThe metabolism of Propofol can be decreased when combined with Mirabegron.Approved
MirtazapinePropofol may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved
MitotaneThe serum concentration of Propofol can be decreased when it is combined with Mitotane.Approved
MoclobemideThe metabolism of Propofol can be decreased when combined with Moclobemide.Approved
ModafinilThe serum concentration of Propofol can be decreased when it is combined with Modafinil.Approved, Investigational
MoexiprilThe risk or severity of adverse effects can be increased when Moexipril is combined with Propofol.Approved
MolindoneThe risk or severity of adverse effects can be increased when Propofol is combined with Molindone.Approved
MorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Propofol.Approved, Investigational
MoxifloxacinPropofol may increase the QTc-prolonging activities of Moxifloxacin.Approved, Investigational
MoxonidineThe risk or severity of adverse effects can be increased when Moxonidine is combined with Propofol.Approved
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Propofol.Approved, Investigational
NadololThe risk or severity of adverse effects can be increased when Nadolol is combined with Propofol.Approved
NafcillinThe serum concentration of Propofol can be decreased when it is combined with Nafcillin.Approved
NalbuphineThe risk or severity of adverse effects can be increased when Propofol is combined with Nalbuphine.Approved
NebivololThe risk or severity of adverse effects can be increased when Nebivolol is combined with Propofol.Approved, Investigational
NefazodoneThe metabolism of Propofol can be decreased when combined with Nefazodone.Approved, Withdrawn
NelfinavirThe metabolism of Propofol can be decreased when combined with Nelfinavir.Approved
NesiritideThe risk or severity of adverse effects can be increased when Nesiritide is combined with Propofol.Approved, Investigational
NetupitantThe serum concentration of Propofol can be increased when it is combined with Netupitant.Approved
NevirapineThe metabolism of Propofol can be increased when combined with Nevirapine.Approved
NicardipineThe metabolism of Propofol can be decreased when combined with Nicardipine.Approved
NicorandilNicorandil may increase the hypotensive activities of Propofol.Approved
NicotineThe metabolism of Propofol can be decreased when combined with Nicotine.Approved
NifedipineThe risk or severity of adverse effects can be increased when Nifedipine is combined with Propofol.Approved
NilotinibPropofol may increase the QTc-prolonging activities of Nilotinib.Approved, Investigational
NilvadipineThe risk or severity of adverse effects can be increased when Nilvadipine is combined with Propofol.Approved
NimodipineThe serum concentration of Nimodipine can be increased when it is combined with Propofol.Approved
NisoldipineThe risk or severity of adverse effects can be increased when Nisoldipine is combined with Propofol.Approved
NitrazepamThe risk or severity of adverse effects can be increased when Propofol is combined with Nitrazepam.Approved
NitrendipineThe risk or severity of adverse effects can be increased when Nitrendipine is combined with Propofol.Approved
Nitric OxideThe risk or severity of adverse effects can be increased when Nitric Oxide is combined with Propofol.Approved
NitroglycerinThe risk or severity of adverse effects can be increased when Nitroglycerin is combined with Propofol.Approved, Investigational
NitroprussideThe risk or severity of adverse effects can be increased when Nitroprusside is combined with Propofol.Approved
Nitrous oxideThe risk or severity of adverse effects can be increased when Propofol is combined with Nitrous oxide.Approved, Vet Approved
NormethadoneThe risk or severity of adverse effects can be increased when Propofol is combined with Normethadone.Approved, Illicit
NortriptylineThe risk or severity of adverse effects can be increased when Propofol is combined with Nortriptyline.Approved
ObinutuzumabThe risk or severity of adverse effects can be increased when Obinutuzumab is combined with Propofol.Approved
OfloxacinPropofol may increase the QTc-prolonging activities of Ofloxacin.Approved
OlanzapineThe risk or severity of adverse effects can be increased when Olanzapine is combined with Propofol.Approved, Investigational
OlaparibThe metabolism of Propofol can be decreased when combined with Olaparib.Approved
OlmesartanThe risk or severity of adverse effects can be increased when Olmesartan is combined with Propofol.Approved, Investigational
OlopatadineThe risk or severity of adverse effects can be increased when Propofol is combined with Olopatadine.Approved
OmeprazoleThe metabolism of Propofol can be decreased when combined with Omeprazole.Approved, Investigational, Vet Approved
OndansetronPropofol may increase the QTc-prolonging activities of Ondansetron.Approved
OpiumThe risk or severity of adverse effects can be increased when Propofol is combined with Opium.Approved, Illicit
OrphenadrinePropofol may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved
OsanetantThe risk or severity of adverse effects can be increased when Propofol is combined with Osanetant.Investigational
OsimertinibThe serum concentration of Propofol can be increased when it is combined with Osimertinib.Approved
OxazepamThe risk or severity of adverse effects can be increased when Propofol is combined with Oxazepam.Approved
OxetacaineThe risk or severity of adverse effects can be increased when Propofol is combined with Oxetacaine.Investigational
OxprenololThe risk or severity of adverse effects can be increased when Propofol is combined with Oxprenolol.Approved
OxybuprocaineThe risk or severity of adverse effects can be increased when Propofol is combined with Oxybuprocaine.Approved
OxycodoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Propofol.Approved, Illicit, Investigational
OxymorphoneThe risk or severity of adverse effects can be increased when Propofol is combined with Oxymorphone.Approved, Investigational, Vet Approved
PaclitaxelThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Propofol.Approved, Vet Approved
PalbociclibThe serum concentration of Propofol can be increased when it is combined with Palbociclib.Approved
PaliperidonePropofol may increase the QTc-prolonging activities of Paliperidone.Approved
PanobinostatThe serum concentration of Propofol can be increased when it is combined with Panobinostat.Approved, Investigational
PantoprazoleThe metabolism of Propofol can be decreased when combined with Pantoprazole.Approved
PapaverineThe risk or severity of adverse effects can be increased when Papaverine is combined with Propofol.Approved
ParaldehydePropofol may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.Approved
ParoxetineThe metabolism of Propofol can be decreased when combined with Paroxetine.Approved, Investigational
PazopanibPropofol may increase the QTc-prolonging activities of Pazopanib.Approved
Peginterferon alfa-2bThe serum concentration of Propofol can be decreased when it is combined with Peginterferon alfa-2b.Approved
PenbutololThe risk or severity of adverse effects can be increased when Penbutolol is combined with Propofol.Approved, Investigational
PentamidinePropofol may increase the QTc-prolonging activities of Pentamidine.Approved
PentazocineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Propofol.Approved, Vet Approved
PentobarbitalThe metabolism of Propofol can be increased when combined with Pentobarbital.Approved, Vet Approved
PerampanelPerampanel may increase the central nervous system depressant (CNS depressant) activities of Propofol.Approved
PerazineThe risk or severity of adverse effects can be increased when Propofol is combined with Perazine.Investigational
PerflutrenPropofol may increase the QTc-prolonging activities of Perflutren.Approved
PerindoprilThe risk or severity of adverse effects can be increased when Perindopril is combined with Propofol.Approved
PerospironeThe risk or severity of adverse effects can be increased when Propofol is combined with Perospirone.Approved
PerphenazineThe risk or severity of adverse effects can be increased when Propofol is combined with Perphenazine.Approved
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Propofol.Approved
PhenelzineThe risk or severity of adverse effects can be increased when Phenelzine is combined with Propofol.Approved
PhenobarbitalThe metabolism of Propofol can be increased when combined with Phenobarbital.Approved
PhenoxybenzamineThe risk or severity of adverse effects can be increased when Phenoxybenzamine is combined with Propofol.Approved
PhenoxyethanolThe risk or severity of adverse effects can be increased when Propofol is combined with Phenoxyethanol.Approved
PhentolamineThe risk or severity of adverse effects can be increased when Phentolamine is combined with Propofol.Approved
PhenytoinThe metabolism of Propofol can be increased when combined with Phenytoin.Approved, Vet Approved
PimozideThe serum concentration of Pimozide can be increased when it is combined with Propofol.Approved
PindololThe risk or severity of adverse effects can be increased when Pindolol is combined with Propofol.Approved
PioglitazoneThe metabolism of Propofol can be decreased when combined with Pioglitazone.Approved, Investigational
PipamperoneThe risk or severity of adverse effects can be increased when Propofol is combined with Pipamperone.Approved
PipotiazineThe risk or severity of adverse effects can be increased when Propofol is combined with Pipotiazine.Approved
PiritramideThe risk or severity of adverse effects can be increased when Propofol is combined with Piritramide.Investigational
PizotifenThe risk or severity of adverse effects can be increased when Propofol is combined with Pizotifen.Approved
PomalidomideThe risk or severity of adverse effects can be increased when Propofol is combined with Pomalidomide.Approved
PosaconazoleThe metabolism of Propofol can be decreased when combined with Posaconazole.Approved, Investigational, Vet Approved
PramipexolePropofol may increase the sedative activities of Pramipexole.Approved, Investigational
PramocaineThe risk or severity of adverse effects can be increased when Propofol is combined with Pramocaine.Approved
PrazepamThe risk or severity of adverse effects can be increased when Propofol is combined with Prazepam.Approved, Illicit
PrazosinThe risk or severity of adverse effects can be increased when Prazosin is combined with Propofol.Approved
PregabalinThe risk or severity of adverse effects can be increased when Pregabalin is combined with Propofol.Approved, Illicit, Investigational
PregnanoloneThe risk or severity of adverse effects can be increased when Propofol is combined with Pregnanolone.Investigational
PrilocaineThe risk or severity of adverse effects can be increased when Prilocaine is combined with Propofol.Approved
PrimaquinePropofol may increase the QTc-prolonging activities of Primaquine.Approved
PrimidoneThe metabolism of Propofol can be increased when combined with Primidone.Approved, Vet Approved
ProcainamidePropofol may increase the QTc-prolonging activities of Procainamide.Approved
ProcaineThe risk or severity of adverse effects can be increased when Procaine is combined with Propofol.Approved, Investigational, Vet Approved
ProchlorperazineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Propofol.Approved, Vet Approved
PromazinePropofol may increase the QTc-prolonging activities of Promazine.Approved, Vet Approved
PromethazineThe risk or severity of adverse effects can be increased when Propofol is combined with Promethazine.Approved
PropafenonePropofol may increase the QTc-prolonging activities of Propafenone.Approved
ProparacaineThe risk or severity of adverse effects can be increased when Proparacaine is combined with Propofol.Approved, Vet Approved
PropoxycaineThe risk or severity of adverse effects can be increased when Propofol is combined with Propoxycaine.Approved
PropranololThe risk or severity of adverse effects can be increased when Propranolol is combined with Propofol.Approved, Investigational
ProtriptylineThe risk or severity of adverse effects can be increased when Propofol is combined with Protriptyline.Approved
PSD502The risk or severity of adverse effects can be increased when Propofol is combined with PSD502.Investigational
PyrimethamineThe metabolism of Propofol can be decreased when combined with Pyrimethamine.Approved, Vet Approved
QuazepamThe serum concentration of Propofol can be increased when it is combined with Quazepam.Approved, Illicit
QuetiapinePropofol may increase the QTc-prolonging activities of Quetiapine.Approved
QuinaprilThe risk or severity of adverse effects can be increased when Quinapril is combined with Propofol.Approved, Investigational
QuinidinePropofol may increase the QTc-prolonging activities of Quinidine.Approved
QuininePropofol may increase the QTc-prolonging activities of Quinine.Approved
RabeprazoleThe metabolism of Propofol can be decreased when combined with Rabeprazole.Approved, Investigational
RacloprideThe risk or severity of adverse effects can be increased when Propofol is combined with Raclopride.Investigational
RamelteonThe risk or severity of adverse effects can be increased when Propofol is combined with Ramelteon.Approved, Investigational
RamiprilThe risk or severity of adverse effects can be increased when Ramipril is combined with Propofol.Approved
RanolazineThe metabolism of Propofol can be decreased when combined with Ranolazine.Approved, Investigational
RasagilineThe risk or severity of adverse effects can be increased when Propofol is combined with Rasagiline.Approved
RemifentanilThe risk or severity of adverse effects can be increased when Propofol is combined with Remifentanil.Approved
RemoxiprideThe risk or severity of adverse effects can be increased when Remoxipride is combined with Propofol.Approved, Withdrawn
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Propofol.Approved
RifabutinThe metabolism of Propofol can be increased when combined with Rifabutin.Approved
RifampicinRifampicin may increase the hypotensive activities of Propofol.Approved
RifapentineThe metabolism of Propofol can be increased when combined with Rifapentine.Approved
RiociguatThe risk or severity of adverse effects can be increased when Riociguat is combined with Propofol.Approved
RisperidonePropofol may increase the hypotensive activities of Risperidone.Approved, Investigational
RitanserinThe risk or severity of adverse effects can be increased when Propofol is combined with Ritanserin.Investigational
RitonavirThe metabolism of Propofol can be decreased when combined with Ritonavir.Approved, Investigational
RolapitantThe metabolism of Propofol can be decreased when combined with Rolapitant.Approved
RomifidineThe risk or severity of adverse effects can be increased when Propofol is combined with Romifidine.Vet Approved
RopinirolePropofol may increase the sedative activities of Ropinirole.Approved, Investigational
RopivacaineThe serum concentration of Ropivacaine can be increased when it is combined with Propofol.Approved
RosiglitazoneThe metabolism of Propofol can be decreased when combined with Rosiglitazone.Approved, Investigational
RotigotinePropofol may increase the sedative activities of Rotigotine.Approved
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Propofol.Approved
S-EthylisothioureaThe risk or severity of adverse effects can be increased when Propofol is combined with S-Ethylisothiourea.Experimental
SacubitrilThe risk or severity of adverse effects can be increased when Propofol is combined with Sacubitril.Approved
Sage 547The risk or severity of adverse effects can be increased when Propofol is combined with Sage 547.Investigational
SaquinavirThe metabolism of Propofol can be decreased when combined with Saquinavir.Approved, Investigational
ScopolamineThe risk or severity of adverse effects can be increased when Propofol is combined with Scopolamine.Approved
SecobarbitalThe metabolism of Propofol can be increased when combined with Secobarbital.Approved, Vet Approved
SelegilineThe risk or severity of adverse effects can be increased when Propofol is combined with Selegiline.Approved, Investigational, Vet Approved
SertindoleThe risk or severity of adverse effects can be increased when Propofol is combined with Sertindole.Approved, Withdrawn
SertralineThe metabolism of Propofol can be decreased when combined with Sertraline.Approved
SevofluraneThe risk or severity of adverse effects can be increased when Propofol is combined with Sevoflurane.Approved, Vet Approved
SildenafilThe metabolism of Propofol can be decreased when combined with Sildenafil.Approved, Investigational
SiltuximabThe serum concentration of Propofol can be decreased when it is combined with Siltuximab.Approved
SimeprevirThe serum concentration of Propofol can be increased when it is combined with Simeprevir.Approved
Sodium NitriteThe risk or severity of adverse effects can be increased when Propofol is combined with Sodium Nitrite.Approved
Sodium oxybateSodium oxybate may increase the central nervous system depressant (CNS depressant) activities of Propofol.Approved
SorafenibThe metabolism of Propofol can be decreased when combined with Sorafenib.Approved, Investigational
SotalolPropofol may increase the QTc-prolonging activities of Sotalol.Approved
SpironolactoneThe risk or severity of adverse effects can be increased when Spironolactone is combined with Propofol.Approved
St. John's WortThe serum concentration of Propofol can be decreased when it is combined with St. John's Wort.Nutraceutical
StiripentolThe serum concentration of Propofol can be increased when it is combined with Stiripentol.Approved
StreptokinaseThe risk or severity of adverse effects can be increased when Propofol is combined with Streptokinase.Approved
SufentanilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Propofol.Approved, Investigational
SulfadiazineThe metabolism of Propofol can be decreased when combined with Sulfadiazine.Approved, Vet Approved
SulfamethoxazoleThe metabolism of Propofol can be decreased when combined with Sulfamethoxazole.Approved
SulfisoxazoleThe metabolism of Propofol can be decreased when combined with Sulfisoxazole.Approved, Vet Approved
SulpirideThe risk or severity of adverse effects can be increased when Sulpiride is combined with Propofol.Approved
SuvorexantPropofol may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved
TamoxifenThe metabolism of Propofol can be decreased when combined with Tamoxifen.Approved
TamsulosinThe risk or severity of adverse effects can be increased when Propofol is combined with Tamsulosin.Approved, Investigational
TandospironeThe risk or severity of adverse effects can be increased when Propofol is combined with Tandospirone.Investigational
TapentadolTapentadol may increase the central nervous system depressant (CNS depressant) activities of Propofol.Approved
TasimelteonThe risk or severity of adverse effects can be increased when Propofol is combined with Tasimelteon.Approved
TelaprevirThe metabolism of Propofol can be decreased when combined with Telaprevir.Approved
TelavancinPropofol may increase the QTc-prolonging activities of Telavancin.Approved
TelithromycinThe metabolism of Propofol can be decreased when combined with Telithromycin.Approved
TelmisartanThe risk or severity of adverse effects can be increased when Telmisartan is combined with Propofol.Approved, Investigational
TemazepamThe risk or severity of adverse effects can be increased when Temazepam is combined with Propofol.Approved
TenofovirThe metabolism of Propofol can be decreased when combined with Tenofovir.Approved, Investigational
TerazosinThe risk or severity of adverse effects can be increased when Terazosin is combined with Propofol.Approved
TerbinafineThe metabolism of Propofol can be decreased when combined with Terbinafine.Approved, Investigational, Vet Approved
TeriflunomideThe serum concentration of Propofol can be decreased when it is combined with Teriflunomide.Approved
TetrabenazinePropofol may increase the QTc-prolonging activities of Tetrabenazine.Approved
TetracaineThe risk or severity of adverse effects can be increased when Propofol is combined with Tetracaine.Approved, Vet Approved
TetrodotoxinThe risk or severity of adverse effects can be increased when Propofol is combined with Tetrodotoxin.Investigational
ThalidomidePropofol may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved, Investigational, Withdrawn
TheophyllineThe metabolism of Propofol can be decreased when combined with Theophylline.Approved
ThiamylalThe risk or severity of adverse effects can be increased when Propofol is combined with Thiamylal.Approved, Vet Approved
ThiopentalThe risk or severity of adverse effects can be increased when Thiopental is combined with Propofol.Approved, Vet Approved
ThioridazineThe serum concentration of Thioridazine can be increased when it is combined with Propofol.Approved
ThiotepaThe metabolism of Propofol can be decreased when combined with Thiotepa.Approved
ThiothixeneThe risk or severity of adverse effects can be increased when Propofol is combined with Thiothixene.Approved
TiagabineThe risk or severity of adverse effects can be increased when Propofol is combined with Tiagabine.Approved
TiaprideThe risk or severity of adverse effects can be increased when Propofol is combined with Tiapride.Investigational
TicagrelorThe metabolism of Propofol can be decreased when combined with Ticagrelor.Approved
TiclopidineThe metabolism of Propofol can be decreased when combined with Ticlopidine.Approved
TiletamineThe risk or severity of adverse effects can be increased when Propofol is combined with Tiletamine.Vet Approved
TimololThe risk or severity of adverse effects can be increased when Timolol is combined with Propofol.Approved
TipranavirThe metabolism of Propofol can be decreased when combined with Tipranavir.Approved, Investigational
TizanidineThe serum concentration of Tizanidine can be increased when it is combined with Propofol.Approved
TocilizumabThe serum concentration of Propofol can be decreased when it is combined with Tocilizumab.Approved
TolazolineThe risk or severity of adverse effects can be increased when Propofol is combined with Tolazoline.Approved, Vet Approved
TolbutamideThe metabolism of Propofol can be decreased when combined with Tolbutamide.Approved
TolcaponeThe risk or severity of adverse effects can be increased when Propofol is combined with Tolcapone.Approved, Withdrawn
TopiramateThe risk or severity of adverse effects can be increased when Propofol is combined with Topiramate.Approved
TorasemideThe risk or severity of adverse effects can be increased when Torasemide is combined with Propofol.Approved
ToremifenePropofol may increase the QTc-prolonging activities of Toremifene.Approved, Investigational
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Propofol.Approved, Investigational
TrandolaprilThe risk or severity of adverse effects can be increased when Trandolapril is combined with Propofol.Approved
Trans-2-PhenylcyclopropylamineThe risk or severity of adverse effects can be increased when Propofol is combined with Trans-2-Phenylcyclopropylamine.Experimental
TranylcypromineThe metabolism of Propofol can be decreased when combined with Tranylcypromine.Approved
TrazodoneThe risk or severity of adverse effects can be increased when Trazodone is combined with Propofol.Approved, Investigational
TretinoinThe risk or severity of adverse effects can be increased when Propofol is combined with Tretinoin.Approved, Investigational, Nutraceutical
TriamtereneThe risk or severity of adverse effects can be increased when Triamterene is combined with Propofol.Approved
TriazolamThe risk or severity of adverse effects can be increased when Propofol is combined with Triazolam.Approved
TrifluoperazineThe risk or severity of adverse effects can be increased when Propofol is combined with Trifluoperazine.Approved
TriflupromazineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Propofol.Approved, Vet Approved
TrimethoprimThe metabolism of Propofol can be decreased when combined with Trimethoprim.Approved, Vet Approved
TrimipramineThe risk or severity of adverse effects can be increased when Propofol is combined with Trimipramine.Approved
TriprolidineThe risk or severity of adverse effects can be increased when Propofol is combined with Triprolidine.Approved
Uc1010The risk or severity of adverse effects can be increased when Propofol is combined with Uc1010.Investigational
Valproic AcidThe risk or severity of adverse effects can be increased when Valproic Acid is combined with Propofol.Approved, Investigational
ValsartanThe metabolism of Propofol can be decreased when combined with Valsartan.Approved, Investigational
VandetanibPropofol may increase the QTc-prolonging activities of Vandetanib.Approved
VemurafenibThe serum concentration of Propofol can be increased when it is combined with Vemurafenib.Approved
VenlafaxineThe metabolism of Propofol can be decreased when combined with Venlafaxine.Approved
VerapamilThe metabolism of Propofol can be decreased when combined with Verapamil.Approved
VigabatrinThe risk or severity of adverse effects can be increased when Propofol is combined with Vigabatrin.Approved
VoriconazoleThe metabolism of Propofol can be decreased when combined with Voriconazole.Approved, Investigational
VortioxetineThe risk or severity of adverse effects can be increased when Propofol is combined with Vortioxetine.Approved
XylazineThe risk or severity of adverse effects can be increased when Propofol is combined with Xylazine.Vet Approved
ZafirlukastThe metabolism of Propofol can be decreased when combined with Zafirlukast.Approved, Investigational
ZaleplonThe risk or severity of adverse effects can be increased when Propofol is combined with Zaleplon.Approved, Illicit, Investigational
ZiconotideThe risk or severity of adverse effects can be increased when Propofol is combined with Ziconotide.Approved
ZimelidineThe risk or severity of adverse effects can be increased when Propofol is combined with Zimelidine.Withdrawn
ZiprasidonePropofol may increase the QTc-prolonging activities of Ziprasidone.Approved
ZolazepamThe risk or severity of adverse effects can be increased when Propofol is combined with Zolazepam.Vet Approved
ZolpidemPropofol may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved
ZonisamideThe risk or severity of adverse effects can be increased when Propofol is combined with Zonisamide.Approved, Investigational
ZopicloneThe risk or severity of adverse effects can be increased when Propofol is combined with Zopiclone.Approved
ZotepineThe risk or severity of adverse effects can be increased when Propofol is combined with Zotepine.Approved
ZuclopenthixolPropofol may increase the QTc-prolonging activities of Zuclopenthixol.Approved, Investigational
Food InteractionsNot Available
References
Synthesis Reference

John R. Carpenter, “Propofol-based anesthetic and method of making same.” U.S. Patent US6150423, issued May, 1977.

US6150423
General References
  1. Vasile B, Rasulo F, Candiani A, Latronico N: The pathophysiology of propofol infusion syndrome: a simple name for a complex syndrome. Intensive Care Med. 2003 Sep;29(9):1417-25. Epub 2003 Aug 6. [PubMed:12904852 ]
  2. Ke JJ, Zhan J, Feng XB, Wu Y, Rao Y, Wang YL: A comparison of the effect of total intravenous anaesthesia with propofol and remifentanil and inhalational anaesthesia with isoflurane on the release of pro- and anti-inflammatory cytokines in patients undergoing open cholecystectomy. Anaesth Intensive Care. 2008 Jan;36(1):74-8. [PubMed:18326136 ]
  3. Hong JY, Kang YS, Kil HK: Anaesthesia for day case excisional breast biopsy: propofol-remifentanil compared with sevoflurane-nitrous oxide. Eur J Anaesthesiol. 2008 Jun;25(6):460-7. doi: 10.1017/S026502150800375X. Epub 2008 Feb 26. [PubMed:18298873 ]
External Links
ATC CodesN01AX10
AHFS Codes
  • 28:04.92
PDB EntriesNot Available
FDA labelDownload (168 KB)
MSDSDownload (71.9 KB)
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9955
Blood Brain Barrier+0.9381
Caco-2 permeable+0.9153
P-glycoprotein substrateNon-substrate0.722
P-glycoprotein inhibitor INon-inhibitor0.9343
P-glycoprotein inhibitor IINon-inhibitor0.9883
Renal organic cation transporterNon-inhibitor0.9036
CYP450 2C9 substrateNon-substrate0.7352
CYP450 2D6 substrateSubstrate0.7838
CYP450 3A4 substrateNon-substrate0.5667
CYP450 1A2 substrateInhibitor0.9107
CYP450 2C9 inhibitorNon-inhibitor0.907
CYP450 2D6 inhibitorNon-inhibitor0.9368
CYP450 2C19 inhibitorNon-inhibitor0.9026
CYP450 3A4 inhibitorNon-inhibitor0.9196
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.7429
Ames testNon AMES toxic0.9282
CarcinogenicityNon-carcinogens0.7195
BiodegradationNot ready biodegradable0.7808
Rat acute toxicity2.2996 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.8987
hERG inhibition (predictor II)Non-inhibitor0.9087
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • App pharmaceuticals llc
  • Bedford laboratories div ben venue laboratories inc
  • Hospira inc
  • Teva parenteral medicines inc
Packagers
Dosage forms
FormRouteStrength
EmulsionIntravenous1 %
Injection, emulsionIntravenous10 mg/mL
EmulsionIntravenous10 mg
Prices
Unit descriptionCostUnit
Diprivan 10 mg/ml vial0.93USD ml
Propoven 1000 mg/100 ml vial0.19USD ml
Propoven 200 mg/20 ml ampul0.19USD ml
Propoven 500 mg/50 ml vial0.19USD ml
Propofol 10 mg/ml vial0.13USD ml
Propofol 1% emulsion vial0.1USD ml
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
CA2212794 No2000-09-122015-03-17Canada
US5714520 Yes1995-09-222015-09-22Us
US5731355 Yes1995-09-222015-09-22Us
US5731356 Yes1995-09-222015-09-22Us
US5908869 Yes1995-09-222015-09-22Us
US8476010 Yes2005-06-012025-06-01Us
Properties
StateLiquid
Experimental Properties
PropertyValueSource
melting point18 °CPhysProp
boiling point256 °CPhysProp
water solubility124 mg/LNot Available
logP3.79HANSCH,C ET AL. (1995)
pKa11.1 (at 20 °C)SERJEANT,EP & DEMPSEY,B (1979)
Predicted Properties
PropertyValueSource
Water Solubility0.158 mg/mLALOGPS
logP3.81ALOGPS
logP4.16ChemAxon
logS-3ALOGPS
pKa (Strongest Acidic)10.98ChemAxon
pKa (Strongest Basic)-5ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count1ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area20.23 Å2ChemAxon
Rotatable Bond Count2ChemAxon
Refractivity56.42 m3·mol-1ChemAxon
Polarizability21.61 Å3ChemAxon
Number of Rings1ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Download (7.9 KB)
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
MSMass Spectrum (Electron Ionization)splash10-03di-2900000000-52d81dde2dccf378a450View in MoNA
1D NMR1H NMR SpectrumNot Available
1D NMR13C NMR SpectrumNot Available
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as cumenes. These are aromatic compounds containing a prop-2-ylbenzene moiety.
KingdomOrganic compounds
Super ClassBenzenoids
ClassBenzene and substituted derivatives
Sub ClassCumenes
Direct ParentCumenes
Alternative Parents
Substituents
  • Phenylpropane
  • Cumene
  • Phenol
  • Hydrocarbon derivative
  • Organooxygen compound
  • Aromatic homomonocyclic compound
Molecular FrameworkAromatic homomonocyclic compounds
External Descriptors

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
potentiator
General Function:
Inhibitory extracellular ligand-gated ion channel activity
Specific Function:
Component of the heteropentameric receptor for GABA, the major inhibitory neurotransmitter in the vertebrate brain. Functions also as histamine receptor and mediates cellular responses to histamine. Functions as receptor for diazepines and various anesthetics, such as pentobarbital; these are bound at a separate allosteric effector binding site. Functions as ligand-gated chloride channel.
Gene Name:
GABRB2
Uniprot ID:
P47870
Molecular Weight:
59149.895 Da
References
  1. Franks NP: Molecular targets underlying general anaesthesia. Br J Pharmacol. 2006 Jan;147 Suppl 1:S72-81. [PubMed:16402123 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
potentiator
General Function:
Gaba-gated chloride ion channel activity
Specific Function:
Component of the heteropentameric receptor for GABA, the major inhibitory neurotransmitter in the vertebrate brain. Functions also as histamine receptor and mediates cellular responses to histamine. Functions as receptor for diazepines and various anesthetics, such as pentobarbital; these are bound at a separate allosteric effector binding site. Functions as ligand-gated chloride channel.
Gene Name:
GABRB3
Uniprot ID:
P28472
Molecular Weight:
54115.04 Da
References
  1. Franks NP: Molecular targets underlying general anaesthesia. Br J Pharmacol. 2006 Jan;147 Suppl 1:S72-81. [PubMed:16402123 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Voltage-gated sodium channel activity
Specific Function:
This protein mediates the voltage-dependent sodium ion permeability of excitable membranes. Assuming opened or closed conformations in response to the voltage difference across the membrane, the protein forms a sodium-selective channel through which Na(+) ions may pass in accordance with their electrochemical gradient. This sodium channel may be present in both denervated and innervated skeleta...
Gene Name:
SCN4A
Uniprot ID:
P35499
Molecular Weight:
208059.175 Da
References
  1. Haeseler G, Karst M, Foadi N, Gudehus S, Roeder A, Hecker H, Dengler R, Leuwer M: High-affinity blockade of voltage-operated skeletal muscle and neuronal sodium channels by halogenated propofol analogues. Br J Pharmacol. 2008 Sep;155(2):265-75. doi: 10.1038/bjp.2008.255. Epub 2008 Jun 23. [PubMed:18574460 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Voltage-gated sodium channel activity
Specific Function:
Mediates the voltage-dependent sodium ion permeability of excitable membranes. Assuming opened or closed conformations in response to the voltage difference across the membrane, the protein forms a sodium-selective channel through which Na(+) ions may pass in accordance with their electrochemical gradient.
Gene Name:
SCN2A
Uniprot ID:
Q99250
Molecular Weight:
227972.64 Da
References
  1. Haeseler G, Karst M, Foadi N, Gudehus S, Roeder A, Hecker H, Dengler R, Leuwer M: High-affinity blockade of voltage-operated skeletal muscle and neuronal sodium channels by halogenated propofol analogues. Br J Pharmacol. 2008 Sep;155(2):265-75. doi: 10.1038/bjp.2008.255. Epub 2008 Jun 23. [PubMed:18574460 ]
Kind
Protein group
Organism
Human
Pharmacological action
yes
Actions
positive allosteric modulator
General Function:
Inhibitory extracellular ligand-gated ion channel activity
Specific Function:
Component of the heteropentameric receptor for GABA, the major inhibitory neurotransmitter in the vertebrate brain. Functions also as histamine receptor and mediates cellular responses to histamine. Functions as receptor for diazepines and various anesthetics, such as pentobarbital; these are bound at a separate allosteric effector binding site. Functions as ligand-gated chloride channel (By similarity).
Components:
NameUniProt IDDetails
Gamma-aminobutyric acid receptor subunit alpha-1P14867 Details
Gamma-aminobutyric acid receptor subunit alpha-2P47869 Details
Gamma-aminobutyric acid receptor subunit alpha-3P34903 Details
Gamma-aminobutyric acid receptor subunit alpha-4P48169 Details
Gamma-aminobutyric acid receptor subunit alpha-5P31644 Details
Gamma-aminobutyric acid receptor subunit alpha-6Q16445 Details
Gamma-aminobutyric acid receptor subunit beta-1P18505 Details
Gamma-aminobutyric acid receptor subunit beta-2P47870 Details
Gamma-aminobutyric acid receptor subunit beta-3P28472 Details
Gamma-aminobutyric acid receptor subunit deltaO14764 Details
Gamma-aminobutyric acid receptor subunit epsilonP78334 Details
Gamma-aminobutyric acid receptor subunit gamma-1Q8N1C3 Details
Gamma-aminobutyric acid receptor subunit gamma-2P18507 Details
Gamma-aminobutyric acid receptor subunit gamma-3Q99928 Details
Gamma-aminobutyric acid receptor subunit piO00591 Details
Gamma-aminobutyric acid receptor subunit thetaQ9UN88 Details
References
  1. ChEMBL Compound Report Card [Link]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. This enzyme contributes to the wide pharmacokinetics variability of the metabolism of drugs such as S-warfarin, diclofenac, phenyto...
Gene Name:
CYP2C9
Uniprot ID:
P11712
Molecular Weight:
55627.365 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014 ]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. Acts as a 1,4-cineole 2-exo-monooxygenase.
Gene Name:
CYP2B6
Uniprot ID:
P20813
Molecular Weight:
56277.81 Da
References
  1. Walsky RL, Astuccio AV, Obach RS: Evaluation of 227 drugs for in vitro inhibition of cytochrome P450 2B6. J Clin Pharmacol. 2006 Dec;46(12):1426-38. [PubMed:17101742 ]
  2. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014 ]
  3. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid binding
Specific Function:
UDPGT is of major importance in the conjugation and subsequent elimination of potentially toxic xenobiotics and endogenous compounds. Isoform 2 lacks transferase activity but acts as a negative regulator of isoform 1.
Gene Name:
UGT1A8
Uniprot ID:
Q9HAW9
Molecular Weight:
59741.035 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Retinoic acid binding
Specific Function:
UDPGT is of major importance in the conjugation and subsequent elimination of potentially toxic xenobiotics and endogenous compounds. This isoform has specificity for phenols. Isoform 2 lacks transferase activity but acts as a negative regulator of isoform 1.
Gene Name:
UGT1A9
Uniprot ID:
O60656
Molecular Weight:
59940.495 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014 ]
  2. Takahashi H, Maruo Y, Mori A, Iwai M, Sato H, Takeuchi Y: Effect of D256N and Y483D on propofol glucuronidation by human uridine 5'-diphosphate glucuronosyltransferase (UGT1A9). Basic Clin Pharmacol Toxicol. 2008 Aug;103(2):131-6. doi: 10.1111/j.1742-7843.2008.00247.x. [PubMed:18816295 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Steroid binding
Specific Function:
UDPGT is of major importance in the conjugation and subsequent elimination of potentially toxic xenobiotics and endogenous compounds. This isoform glucuronidates bilirubin IX-alpha to form both the IX-alpha-C8 and IX-alpha-C12 monoconjugates and diconjugate. Is also able to catalyze the glucuronidation of 17beta-estradiol, 17alpha-ethinylestradiol, 1-hydroxypyrene, 4-methylumbelliferone, 1-naph...
Gene Name:
UGT1A1
Uniprot ID:
P22309
Molecular Weight:
59590.91 Da
References
  1. Mano Y, Usui T, Kamimura H: Substrate-dependent modulation of UDP-glucuronosyltransferase 1A1 (UGT1A1) by propofol in recombinant human UGT1A1 and human liver microsomes. Basic Clin Pharmacol Toxicol. 2007 Sep;101(3):211-4. [PubMed:17697043 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Fatty acid amide hydrolase activity
Specific Function:
Degrades bioactive fatty acid amides like oleamide, the endogenous cannabinoid, anandamide and myristic amide to their corresponding acids, thereby serving to terminate the signaling functions of these molecules. Hydrolyzes polyunsaturated substrate anandamide preferentially as compared to monounsaturated substrates.
Gene Name:
FAAH
Uniprot ID:
O00519
Molecular Weight:
63065.28 Da
References
  1. Zhu F, Han B, Kumar P, Liu X, Ma X, Wei X, Huang L, Guo Y, Han L, Zheng C, Chen Y: Update of TTD: Therapeutic Target Database. Nucleic Acids Res. 2010 Jan;38(Database issue):D787-91. doi: 10.1093/nar/gkp1014. Epub 2009 Nov 20. [PubMed:19933260 ]
  2. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. [PubMed:10592235 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Metabolizes several precarcinogens, drugs, and solvents to reactive metabolites. Inactivates a number of drugs and xenobiotics and also bioactivates many xenobiotic substrates to their hepatotoxic or carcinogenic forms.
Gene Name:
CYP2E1
Uniprot ID:
P05181
Molecular Weight:
56848.42 Da
References
  1. Chen TL, Ueng TH, Chen SH, Lee PH, Fan SZ, Liu CC: Human cytochrome P450 mono-oxygenase system is suppressed by propofol. Br J Anaesth. 1995 May;74(5):558-62. [PubMed:7772432 ]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Oxygen binding
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, retinoid and xenobiotics. Preferentially oxidizes 17beta-estradiol to the carcinogenic 4-hydroxy derivative, and a variety of procarcinogenic compou...
Gene Name:
CYP1B1
Uniprot ID:
Q16678
Molecular Weight:
60845.33 Da
References
  1. Chen TL, Ueng TH, Chen SH, Lee PH, Fan SZ, Liu CC: Human cytochrome P450 mono-oxygenase system is suppressed by propofol. Br J Anaesth. 1995 May;74(5):558-62. [PubMed:7772432 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Vitamin d 24-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics.
Gene Name:
CYP1A1
Uniprot ID:
P04798
Molecular Weight:
58164.815 Da
References
  1. Chen TL, Ueng TH, Chen SH, Lee PH, Fan SZ, Liu CC: Human cytochrome P450 mono-oxygenase system is suppressed by propofol. Br J Anaesth. 1995 May;74(5):558-62. [PubMed:7772432 ]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. Most active in catalyzing 2-hydroxylation. Caffeine is metabolized primarily by cytochrome CYP1A2 in the liver through an initial N...
Gene Name:
CYP1A2
Uniprot ID:
P05177
Molecular Weight:
58293.76 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Exhibits a high coumarin 7-hydroxylase activity. Can act in the hydroxylation of the anti-cancer drugs cyclophosphamide and ifosphamide. Competent in the metabolic activation of aflatoxin B1. Constitutes the major nicotine C-oxidase. Acts as a 1,4-cineole 2-exo-monooxygenase. Possesses low phenacetin O-deethylation activity.
Gene Name:
CYP2A6
Uniprot ID:
P11509
Molecular Weight:
56501.005 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics.
Gene Name:
CYP2C18
Uniprot ID:
P33260
Molecular Weight:
55710.075 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of a number of therapeutic agents such as the anticonvulsant drug S-mephenytoin, omeprazole, proguanil, certain barbiturates, diazepam, propranolol, citalopram and imipramine.
Gene Name:
CYP2C19
Uniprot ID:
P33261
Molecular Weight:
55930.545 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. In the epoxidation of arachidonic acid it generates only 14,15- and 11,12-cis-epoxyeicosatrienoic acids. It is the principal enzyme...
Gene Name:
CYP2C8
Uniprot ID:
P10632
Molecular Weight:
55824.275 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic antidepressants.
Gene Name:
CYP2D6
Uniprot ID:
P10635
Molecular Weight:
55768.94 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Molecular Weight:
57342.67 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Protein homodimerization activity
Specific Function:
UDPGT is of major importance in the conjugation and subsequent elimination of potentially toxic xenobiotics and endogenous compounds. This isoform has specificity for phenols. Isoform 3 lacks transferase activity but acts as a negative regulator of isoform 1 (By similarity).
Gene Name:
UGT1A6
Uniprot ID:
P19224
Molecular Weight:
60750.215 Da
References
  1. Gu J, Lu K, Xia P, Tang M, Dai Q, Ma D, Tao G: Pharmacokinetics of propofol and extrahepatic UGT1A6 gene expression in anhepatic rats. Pharmacology. 2009;84(4):219-26. doi: 10.1159/000236523. Epub 2009 Sep 10. [PubMed:19752585 ]

Carriers

Kind
Protein
Organism
Human
Pharmacological action
no
General Function:
Toxic substance binding
Specific Function:
Serum albumin, the main protein of plasma, has a good binding capacity for water, Ca(2+), Na(+), K(+), fatty acids, hormones, bilirubin and drugs. Its main function is the regulation of the colloidal osmotic pressure of blood. Major zinc transporter in plasma, typically binds about 80% of all plasma zinc.
Gene Name:
ALB
Uniprot ID:
P02768
Molecular Weight:
69365.94 Da
References
  1. Bright DP, Adham SD, Lemaire LC, Benavides R, Gruss M, Taylor GW, Smith EH, Franks NP: Identification of anesthetic binding sites on human serum albumin using a novel etomidate photolabel. J Biol Chem. 2007 Apr 20;282(16):12038-47. Epub 2007 Feb 20. [PubMed:17311911 ]
  2. Liu R, Eckenhoff RG: Weak polar interactions confer albumin binding site selectivity for haloether anesthetics. Anesthesiology. 2005 Apr;102(4):799-805. [PubMed:15791110 ]
  3. Sawas AH, Pentyala SN, Rebecchi MJ: Binding of volatile anesthetics to serum albumin: measurements of enthalpy and solvent contributions. Biochemistry. 2004 Oct 5;43(39):12675-85. [PubMed:15449957 ]
  4. Schywalsky M, Ihmsen H, Knoll R, Schwilden H: Binding of propofol to human serum albumin. Arzneimittelforschung. 2005;55(6):303-6. [PubMed:16032968 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on December 07, 2016 03:54